Insights
Regulatory analysis for the people responsible for the decision
Practical explanations of how inspection evidence, company responses, quality-system performance, and remediation are evaluated together.
From Tailwind Pharma
Closing a CAPA is not the same as demonstrating effectiveness
A corrective action plan can be fully executed and still leave FDA's real question unanswered. What implementation evidence, root cause, systemic scope, recurrence, and management rationale actually require.
Read the article01
FDA Inspections
What to do when an inspection is announced or already underway.
Read the guidance02
Form FDA 483 Responses
Evidence, systemic scope, commitments, and the 15-business-day response window.
Read the guidance03
Warning Letters
Why prior remediation was not persuasive and what changes at enterprise level.
Read the guidance04
Quality Systems
Investigations, CAPA effectiveness, management oversight, and sustainable control.
Read the guidance05
Data Integrity
ALCOA+, paper and hybrid records, and oversight across contract partners.
Read the guidance06
FDA Policy & Guidance
Practical interpretation through The Regulatory Mix.
Read the guidance07
Pharmaceutical Manufacturing Compliance
Inspection readiness, PAI preparation, and defensible operations.
Read the guidance08
AI in Pharmaceutical Quality
Technology-supported analysis with accountable human decisions.
Read the guidanceRegulatory Mix
Where sound and AI meet CGMPs, and CGMPs meet practice.
Listen to FDA news, enforcement developments, and pharmaceutical quality topics through Tailwind Pharma’s media channel.